Sectors of Strategic
National Importance.
Bioscience Equity Partners operates two divisions. Life Sciences remains the firm’s anchor sector and the exclusive mandate of Antisoma Venture Capital. Infrastructure & Sovereign Advisory is the firm’s dedicated division for capital-intensive transactions of strategic national importance. Across every sector, the firm structures the deal, anchors or syndicates the capital, and drives the round to close.
01  — Life Sciences
The Firm’s Anchor Sector
The firm’s anchor sector. Bioscience Equity Partners structures, anchors, and executes capital rounds for biotechnology, medical technology, and digital health companies. Antisoma Venture Capital anchors the majority of rounds in this sector at approximately fifty per cent; the remainder is syndicated across the firm’s consortium of sovereign and quasi-sovereign funds. Coverage spans therapeutics, diagnostics, medical devices, and digital health platforms.
- Therapeutics and drug discovery
- Diagnostics and precision medicine
- Medical devices and instrumentation
- Digital health platforms
02  — Energy Infrastructure
Nuclear and Small Modular Reactor Deployment
Bioscience Equity Partners structures, syndicates, and executes energy infrastructure transactions with a focus on nuclear power, including small modular reactor (SMR) deployment. The firm raises and deploys capital for nuclear-enabled platforms supporting agro-biotechnology and food security, and for carbon-free baseload systems underpinning life sciences and industrial resilience. Mandates in this sector typically involve sovereign principals and state-owned enterprises and are closed through the firm’s consortium.
- Nuclear power infrastructure
- Small modular reactor (SMR) deployment
- Carbon-free baseload energy systems
- Nuclear-enabled agricultural platforms
03  — Agricultural Biotechnology
Biological Value Chains at Industrial Scale
Bioscience Equity Partners structures and executes capital transactions across integrated upstream, midstream, and downstream biological value chains, with a focus on biotech-driven agricultural resilience and supply optimisation. The firm raises capital for bioindustrial platforms operating at industrial scale and for agricultural biotechnology transactions of national strategic importance, particularly where food security policy intersects with sovereign investment priorities.
- Agricultural biotechnology and genomics
- Bioindustrial platforms at industrial scale
- Food security infrastructure
- Supply chain resilience technologies
04  — Defence-Adjacent Manufacturing
Strategic Industrial Capability
Bioscience Equity Partners structures and executes capital transactions involving defence-adjacent manufacturing, secure supply chains for critical technologies and biological systems, and dual-use infrastructure at the intersection of national security and life sciences. The firm engages selectively in this sector, working only with sovereign principals and counterparties of established standing.
- Defence-adjacent manufacturing platforms
- Secure critical technology supply chains
- Dual-use biological and industrial infrastructure
- Strategic national capability development
05  — Government & Sovereign Advisory
Public-Private Capital for Strategic National Assets
Bioscience Equity Partners engages directly with ministries, sovereign funds, and state-owned enterprises on public-private capital structuring for strategic national assets. The firm structures privatisations, runs public tender processes, and deploys sovereign capital into industrial-grade mandates from origination through to close.
- Privatisation structuring and execution
- Public tender process management
- Sovereign capital deployment
- Ministry and state-owned enterprise advisory